Detalhe da pesquisa
1.
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Pediatr Blood Cancer
; 65(9): e27217, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29750396